Balasa Dinverno & Foltz’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.43M | Sell |
20,065
-2,046
| -9% | -$148K | 0.09% | 93 |
|
|
2022
Q2 | $1.7M | Buy |
22,111
+3,698
| +20% | +$282K | 0.11% | 78 |
|
|
2022
Q1 | $1.34M | Buy |
18,413
+2,041
| +12% | +$137K | 0.09% | 99 |
|
|
2021
Q4 | $1.02M | Sell |
16,372
-7,145
| -30% | -$419K | 0.07% | 126 |
|
|
2021
Q3 | $1.39M | Buy |
23,517
+168
| +0.7% | +$11.1K | 0.1% | 97 |
|
|
2021
Q2 | $1.56M | Sell |
23,349
-324
| -1% | -$21.1K | 0.11% | 88 |
|
|
2021
Q1 | $1.49M | Sell |
23,673
-1,037
| -4% | -$64.5K | 0.12% | 87 |
|
|
2020
Q4 | $1.53M | Buy |
24,710
+920
| +4% | +$56.6K | 0.13% | 79 |
|
|
2020
Q3 | $1.43M | Buy |
23,790
+978
| +4% | +$58.9K | 0.14% | 69 |
|
|
2020
Q2 | $1.34M | Sell |
22,812
-2,692
| -11% | -$161K | 0.15% | 64 |
|
|
2020
Q1 | $1.42M | Buy |
25,504
+935
| +4% | +$57.1K | 0.18% | 53 |
|
|
2019
Q4 | $1.58M | Buy |
24,569
+7,265
| +42% | +$416K | 0.17% | 60 |
|
|
2019
Q3 | $877K | Sell |
17,304
-384
| -2% | -$18K | 0.1% | 100 |
|
|
2019
Q2 | $802K | Sell |
17,688
-840
| -5% | -$39.1K | 0.09% | 102 |
|
|
2019
Q1 | $884K | Sell |
18,528
-939
| -5% | -$46.8K | 0.11% | 85 |
|
|
2018
Q4 | $1.01M | Sell |
19,467
-4,178
| -18% | -$224K | 0.13% | 75 |
|
|
2018
Q3 | $1.47M | Sell |
23,645
-257
| -1% | -$15.3K | 0.17% | 52 |
|
|
2018
Q2 | $1.32M | Sell |
23,902
-1,325
| -5% | -$71.6K | 0.19% | 50 |
|
|
2018
Q1 | $1.6M | Sell |
25,227
-310
| -1% | -$19.9K | 0.24% | 38 |
|
|
2017
Q4 | $1.56M | Sell |
25,537
-333
| -1% | -$20.8K | 0.23% | 43 |
|
|
2017
Q3 | $1.65M | Sell |
25,870
-1,173
| -4% | -$68.5K | 0.26% | 39 |
|
|
2017
Q2 | $1.51M | Buy |
27,043
+5,756
| +27% | +$313K | 0.25% | 35 |
|
|
2017
Q1 | $1.16M | Buy |
21,287
+9,665
| +83% | +$530K | 0.2% | 42 |
|
|
2016
Q4 | $679K | Buy |
11,622
+82
| +0.7% | +$4.48K | 0.12% | 77 |
|
|
2016
Q3 | $622K | Buy |
11,540
+110
| +1% | +$7.07K | 0.11% | 76 |
|
|
2016
Q2 | $841K | Buy |
11,430
+1,428
| +14% | +$101K | 0.15% | 56 |
|
|
2016
Q1 | $639K | Buy |
10,002
+50
| +0.5% | +$3.15K | 0.11% | 66 |
|
|
2015
Q4 | $685K | Buy |
9,952
+217
| +2% | +$14.3K | 0.12% | 64 |
|
|
2015
Q3 | $576K | Sell |
9,735
-8
| -0.1% | -$508 | 0.1% | 77 |
|
|
2015
Q2 | $648K | Sell |
9,743
-1,394
| -13% | -$91.9K | 0.11% | 66 |
|
|
2015
Q1 | $718K | Sell |
11,137
-1,080
| -9% | -$67.6K | 0.1% | 62 |
|
|
2014
Q4 | $721K | Sell |
12,217
-80
| -0.7% | -$4.51K | 0.1% | 64 |
|
|
2014
Q3 | $629K | Buy |
12,297
+1,250
| +11% | +$62.4K | 0.1% | 67 |
|
|
2014
Q2 | $536K | Sell |
11,047
-310
| -3% | -$15.3K | 0.06% | 74 |
|
|
2014
Q1 | $590K | Buy |
11,357
+1,562
| +16% | +$83.1K | 0.07% | 65 |
|
|
2013
Q4 | $521K | Buy |
9,795
+138
| +1% | +$7.03K | 0.07% | 66 |
|
|
2013
Q3 | $447K | Buy |
9,657
+351
| +4% | +$15.4K | 0.07% | 64 |
|
|
2013
Q2 | $416K | Buy |
+9,306
| New | +$404K | 0.07% | 63 |
|
Other funds holding BMY
Balasa Dinverno & Foltz's BMY Position: Q3 2022 in Review
Balasa Dinverno & Foltz reduced its Bristol-Myers Squibb (BMY) stake by 9.3% in Q3 2022, selling an estimated $148K and leaving 20,065 shares worth $1.43M. The position accounts for 0.09% of the portfolio, ranked #93.
Balasa Dinverno & Foltz first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.7M in Q2 2022. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- Balasa Dinverno & Foltz held 20,065 shares of Bristol-Myers Squibb worth $1.43M as of Q3 2022.
- Balasa Dinverno & Foltz sold 2,046 Bristol-Myers Squibb shares in Q3 2022, an estimated $148K.
- Bristol-Myers Squibb made up 0.09% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #93 holding.
- Balasa Dinverno & Foltz first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
- Balasa Dinverno & Foltz's Bristol-Myers Squibb position peaked at $1.7M in Q2 2022.
- 2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.